Sharks could lead the way to new Lundbeck drugs
Danish drug group Lundbeck struck a research deal with US biotech company Ossianix recently – a company that deals in something as novel as shark antibodies. Lundbeck’s Danish research chief is impressed with the US outfit.
by Benjamin Werner Christensen
It might sound curious and futuristic, but the fact remains that Lundbeck could have drugs based on shark antibodies on their hands sometime in the near future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novel platform could lead to new Lundbeck drugs
For abonnenter
Diamond in the rough in Lundbeck’s pipeline
For abonnenter
Lundbeck eyes solid premium in Genmab field
For abonnenter
